[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypercalciuria\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypercalciuria":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100308878","phase-2-rifampin-in-cyp24a1-related-hypercalcemia-and-hypercalciuria-100308878",false,"NCT03301038","Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria","Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene","RICHH","Inclusion Criteria:\n\n* Males or females age 6 months to 65 years.\n* at least one mutations of CYP24A1\n* Serum and\u002For urinary calcium above the normal reference range for age\n* Serum PTH concentration \\\u003C20 pg\u002Fml\n* Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.\n\nExclusion Criteria:\n\n* Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n* Allergy to rifampin or related medications\n* Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By \"drug-drug\" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.\n* Pregnancy or breastfeeding\n* Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:\n* Aspartate Aminotransferase (AST\u002FSGOT) \\> 2.0 times the upper limit of normal Alanine aminotransferase (ALT\u002FSGPT) \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal Creatinine \\> 2.0 times the upper limit of normal","ALL","6 Months","65 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and\u002For hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.",[28,29,30,31,32,33],"Idiopathic Infantile Hypercalcaemia - Severe Form","Genetic Disease","Hypercalcemia, Idiopathic, of Infancy","Hypercalciuric Hypercalcemia","Idiopathic Infantile Hypercalcemia - Mild Form","Hypercalciuria",[35,36,37,38],"hypercalcemia","nephrocalcinosis","CYP24A1","hypercalciuria","RECRUITING","2026-06-18",{"date":42,"type":43},"2026-06-22","ACTUAL",{"date":45,"type":43},"2018-07-25",{"date":47,"type":22},"2030-12",{"name":49,"class":50},"Children's Hospital of Philadelphia","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":51},"100344931","early-phase-1-the-impact-of-phosphate-metabolism-on-healthy-aging-100344931","NCT03771105","The Impact of Phosphate Metabolism on Healthy Aging","Inclusion Criteria:\n\n* Children above the age of 13 years\n* Younger and older adults with XLH and HHRH with confirmed NPT2c mutations affecting both copies of the NPT2c gene (HHRH) or one copy of the PHEX gene (XLH)\n* Be willing to provide access to prior medical records to determine eligibility including imaging, biochemical, medical, and surgical history data\n* Be willing and able to complete all aspects of the study\n* Be willing to adhere to the study visit schedule and comply with the assessments (in the opinion of the investigator).\n\nExclusion Criteria:\n\n* Subjects will be excluded, if they are children younger than age 13 years\n* Subjects that have other diseases likely to impact bone and mineral metabolism (e.g. renal, hepatic, gastrointestinal disorders, and malignancy),\n* Subjects that are currently pregnant,\n* Subjects that received medical therapy or developed any condition, which in the opinion of the investigator, could present a concern for either subject safety or difficulty with data interpretation.\n* Subjects will be excluded from Aim 2, if they are unable to tolerate supplemental phosphate.","13 Years",{"count":60,"type":22},30,[62],"EARLY_PHASE1","Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis\u002Fnephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) and patients with X-linked hypophosphatemia (XLH).",[65,66,33,67,68],"Hypophosphatemia","Rickets","XLH","HHRH","2026-05-21",{"date":71,"type":43},"2026-05-27",{"date":73,"type":43},"2019-01-01",{"date":75,"type":22},"2028-04",{"name":77,"class":50},"Yale University"]